Selinexor, anti-PD-1 antibody plus Golidocitinib

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Selinexor, anti-PD-1 antibody plus Golidocitinib
Treatment and conditionWhere it standsTrials
Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1